Particle therapy in head and neck cancer—expanding therapeutic options

被引:0
|
作者
Petra Georg
机构
[1] MedAustron Ion Therapy Center,
关键词
Proton; Radiotherapy; Carbon; Ion; Radioresistant;
D O I
暂无
中图分类号
学科分类号
摘要
The management of head and neck tumors is challenging and requires a multidisciplinary approach. Besides the common histology of squamous cell cancer, other histologies like adenoid cystic carcinoma, mucosal melanoma, and adenocarcinoma are often present. These tumors are radioresistant and need high radiation doses. Photon beam therapy is often limited by the normal tissue tolerance, and particle therapy using protons or carbon ions is a valuable treatment option. Due to their dosimetric advantages, protons enable deposition of high tumor doses, while optimally sparing the surrounding tissue. Carbon ions offer the additional advantage of a higher linear energy transfer (LET) which results in a higher biological effectiveness of tumor cell damage. Therefore, while protons can also be used in sterilizing microscopic disease, carbon ions should be considered in large macroscopic disease, where a significant tumor burden has to be managed.
引用
下载
收藏
页码:389 / 394
页数:5
相关论文
共 50 条
  • [1] Particle therapy in head and neck cancer-expanding therapeutic options
    Georg, Petra
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2020, 13 (04) : 389 - 394
  • [2] Proton therapy for head and neck cancer: expanding the therapeutic window
    Leeman, Jonathan E.
    Romesser, Paul B.
    Zhou, Ying
    McBride, Sean
    Riaz, Nadeem
    Sherman, Eric
    Cohen, Marc A.
    Cahlon, Oren
    Lee, Nancy
    LANCET ONCOLOGY, 2017, 18 (05): : E254 - E265
  • [3] The expanding role of systemic therapy in head and neck cancer
    Cohen, EEW
    Lingen, MW
    Vokes, EE
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) : 1743 - 1752
  • [4] Recurrent head and neck cancer - salvage therapy options
    Lukaszczyk-Widel, Beata
    Widel, Maciej
    Skladowski, Krzysztof
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2008, 12 (04): : 187 - 191
  • [5] Current therapy options in recurrent head and neck cancer
    Boehm, A.
    Wichmann, G.
    Mozet, C.
    Dietz, A.
    HNO, 2010, 58 (08) : 762 - 769
  • [6] Cetuximab in the management of locoregionally advanced head and neck cancer: Expanding the treatment options?
    Bourhis, Jean
    Lefebvre, Jean-Louis
    Vermorken, Jan B.
    EUROPEAN JOURNAL OF CANCER, 2010, 46 (11) : 1979 - 1989
  • [7] Checkpoint Inhibition in Head and Neck Cancer: Immune Therapeutic Options, Limitations, and Beyond
    Hoechst, Bastian
    Knolle, Percy A.
    ORL-JOURNAL FOR OTO-RHINO-LARYNGOLOGY HEAD AND NECK SURGERY, 2017, 79 (1-2): : 24 - 33
  • [8] Pembrolizumab and Cetuximab as therapeutic options for ACC in head and neck
    Michaelides, Ioannis
    Fest, Sandra
    Berszin, Michael
    Wiegand, Susanne
    Bohr, Christopher
    Kuenzel, Julian
    Dietz, Andreas
    Pirlich, Markus
    Wichmann, Gunnar
    LARYNGO-RHINO-OTOLOGIE, 2022, 101 (09) : 736 - 740
  • [9] Novel Treatment Options in Head and Neck Cancer
    Schuler, Patrick J.
    Laban, Simon
    Doescher, Johannes
    Bullinger, Lars
    Hoffmann, Thomas K.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (06) : 342 - 346
  • [10] Molecular targeted therapy: novel therapeutic approach for head and neck cancer
    Shrivastava, Swatantra
    Nagi, Ravleen
    Sharma, Saurabh
    Sanadi, Sajid Ahmed Rasul
    Dafallah, Elbadri Taha
    Ragit, Akshay
    THERAPEUTIC DELIVERY, 2020, 11 (10) : 637 - 651